CareDx's First Report Under Final Medicare Rules Will Reveal How Test Limits Actually Work
CareDx Inc (NASDAQ: CDNA) reports Q2 2026 earnings after market close on July 30, 2026 — tomorrow — with analysts expecting the precision medicine company to deliver $0.06 per share on the back of continued momentum in its transplant diagnostics business. After posting a surprise profit last quarter and delivering four consecutive earnings beats, the central question is whether CareDx can sustain its newfound profitability while maintaining the strong revenue growth that has driven shares up over 100% year-to-date.
Part 1: Earnings Preview
CareDx is a precision medicine company focused on transplant care, offering non-invasive blood tests like AlloSure® and AlloMap® that monitor organ rejection in transplant recipients. The company generates revenue primarily from these proprietary diagnostic testing services, which help guide post-transplant patient management at transplant centers nationwide.
For Q2 2026, the consensus estimate calls for earnings of $0.06 per share, with revenue expected at $110 million. Last quarter (Q1 2026), CareDx reported actual EPS of $0.05, marking a significant turnaround from the prior year's loss. Compared to Q2 2025 — when the company posted a loss of $0.16 per share — the year-over-year improvement of $0.22 per share represents a dramatic 137.5% growth rate and would mark the company's second consecutive profitable quarter.
Three key themes define this earnings story:
Test Volume Growth and Market Penetration: Investors will focus intensely on adoption rates for CareDx's core AlloSure® and AlloMap® tests at transplant centers. Volume trends directly drive revenue growth and indicate whether the company is successfully expanding its market share in the competitive transplant diagnostics field. Management commentary on testing volumes and new customer wins will be critical.
Path to Sustainable Profitability: After years of losses, CareDx posted its first profit in Q1 2026 with a 2.4% net margin. The question now is whether this marks an inflection point or a temporary blip. Investors will scrutinize gross margin performance (which hit 71.4% last quarter), operating expense discipline, and cash burn to assess whether profitability can be sustained.
Reimbursement Landscape and Regulatory Progress: Reimbursement developments from payers and any updates on regulatory approvals for expanded testing indications remain crucial long-term drivers. Partnership announcements and geographic expansion efforts also factor into the growth trajectory, as CareDx seeks to broaden its addressable market beyond current transplant monitoring applications.
Analysts have grown increasingly bullish heading into the report, with the stock carrying a consensus "Moderate Buy" rating and an average price target of $33.00. The strong momentum in recent quarters has shifted sentiment, though some caution remains given the company's history of volatility and the challenge of maintaining profitability while investing for growth.
Part 2: Historical Earnings Performance
CareDx has delivered four consecutive earnings beats, establishing a clear pattern of outperformance against analyst expectations. Most recently in Q1 2026, the company reported $0.05 per share against an estimate of -$0.11, representing a massive +145.45% surprise. The prior quarter (Q3 2025) saw an even larger beat of +127.27%, posting $0.03 versus expectations of -$0.11.
The earnings trajectory shows dramatic improvement from the company's loss-making history. Q2 2025 saw a -45.45% miss with a loss of $0.16 per share, but since then CareDx has consistently exceeded expectations by wide margins. The Q4 2025 result was complicated by what appears to be an unusual situation where the company posted a loss of $0.08 against a breakeven estimate, though the surprise percentage calculation was unavailable.
The pattern is unmistakable: after struggling in mid-2025, CareDx has found its footing with back-to-back profitable quarters and substantial beats. The consistency of recent outperformance — with surprise margins exceeding 100% in two of the last three quarters — suggests the company may be entering a new phase of operational execution that analysts are still catching up to in their models.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $-0.11 | $-0.16 | -45.45% | Miss |
| Sep 2025 | $-0.11 | $0.03 | +127.27% | Beat |
| Dec 2025 | $0.00 | $-0.08 | N/A | Miss |
| Mar 2026 | $-0.11 | $0.05 | +145.45% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
CareDx reports after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual earnings release.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-04-28 | +$0.06 (+0.27%) | $0.93 (4.26%) | -$1.11 (-5.07%) | $5.00 (22.80%) |
| 2026-02-24 | +$0.46 (+2.45%) | $0.85 (4.50%) | -$0.79 (-4.10%) | $1.76 (9.14%) |
| 2025-11-04 | -$0.25 (-1.69%) | $0.50 (3.39%) | +$2.01 (+13.84%) | $2.18 (15.01%) |
| 2025-08-06 | +$0.25 (+1.95%) | $0.90 (7.00%) | -$1.03 (-7.86%) | $1.23 (9.39%) |
| 2025-04-30 | -$1.25 (-6.89%) | $1.16 (6.37%) | -$1.81 (-10.72%) | $2.32 (13.76%) |
| 2025-02-26 | +$0.21 (+1.01%) | $1.23 (5.89%) | -$0.04 (-0.19%) | $2.19 (10.37%) |
| 2024-11-04 | +$0.29 (+1.28%) | $0.87 (3.84%) | -$0.03 (-0.13%) | $2.59 (11.31%) |
| 2024-07-31 | +$1.23 (+6.56%) | $1.58 (8.42%) | +$3.59 (+17.96%) | $5.00 (25.01%) |
| Avg Abs Move | 2.76% | 5.46% | 7.48% | 14.60% |
Historical price action around CareDx earnings shows significant volatility, with an average absolute Day +1 move of 7.48% and an average intraday range of 14.60% on the day following results. The most dramatic recent reaction came after the July 2024 report, when shares surged 17.96% on Day +1 with an intraday range exceeding 25%.
More recent quarters have shown somewhat more muted reactions, though still substantial. The April 2026 earnings triggered a 5.07% decline on Day +1 despite the strong beat, while November 2025 saw a 13.84% surge following another positive surprise. Day 0 moves have been relatively modest, averaging 2.76%, which is typical for after-hours reporters where the market hasn't yet digested the results.
Investors should prepare for meaningful volatility, particularly given the stock's recent momentum and elevated expectations. The historical pattern suggests double-digit percentage swings are entirely possible depending on whether results and guidance meet the market's now-elevated bar.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 23) |
| Expected Move | $2.55 (7.20%) |
| Expected Range | $32.86 to $37.96 |
| Implied Volatility | 72.11% |
The options market is pricing an expected move of 7.20% through the August 21 expiration, which aligns closely with the 7.48% average Day +1 move observed in recent earnings history. This suggests options traders are anticipating typical volatility rather than an outsized reaction, though the stock's recent momentum and profitability inflection could drive moves beyond the expected range if results significantly surprise in either direction.
Part 3: What Analysts Are Saying
Analyst sentiment on CareDx stands at "Moderate Buy" with an average rating of 3.75 out of 5.0, reflecting cautious optimism about the company's turnaround story. The consensus is supported by 3 Strong Buy ratings and 5 Hold ratings, with no sell recommendations currently on the stock. This rating distribution has remained unchanged over the past month, indicating stable sentiment heading into the Q2 report.
The average price target of $33.00 sits 6.8% below the current price of $35.41, suggesting analysts believe the recent rally may have gotten ahead of fundamentals. However, the wide range of targets — from a low of $21.00 to a high of $45.00 — reflects significant disagreement about CareDx's valuation and growth trajectory. The high-end target implies 27% upside from current levels, while the low-end suggests 41% downside risk, underscoring the stock's binary nature as it attempts to prove sustainable profitability.
The unchanged sentiment trend indicates analysts are taking a wait-and-see approach, likely wanting to see multiple quarters of consistent profitability and strong volume growth before becoming more aggressive with their ratings. The concentration of Hold ratings alongside the Strong Buys suggests many analysts acknowledge the positive momentum but remain cautious about valuation after the stock's dramatic year-to-date run.
Part 4: Technical Picture
CareDx enters earnings with an exceptionally strong technical setup, sporting a 100% Buy signal from the Barchart Technical Opinion — a reading that has remained at maximum bullish strength for the past month. The stock has been in a powerful uptrend, trading well above all major moving averages and showing consistent momentum heading into tomorrow's report.
The technical opinion has maintained its "Maximum" strength with a "Strengthening" direction, indicating the uptrend remains intact and is actually gaining power rather than showing signs of exhaustion. This is notable given the stock's substantial year-to-date gains.
Timeframe Analysis:
- Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum with no signs of weakening
- Medium-term (100% Buy): Sustained bullish reading confirms the intermediate trend remains firmly positive
- Long-term (100% Buy): Strong long-term buy signal suggests the broader trend structure supports continued upside
Trend Characteristics: The combination of Maximum strength and Strengthening direction creates an ideal technical environment heading into earnings, suggesting the stock has strong underlying momentum that could amplify a positive surprise.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $36.45 | 50-Day MA | $27.52 |
| 10-Day MA | $37.70 | 100-Day MA | $23.27 |
| 20-Day MA | $33.27 | 200-Day MA | $20.69 |
The stock is currently trading at $35.41, positioned above the 20-day ($33.27), 50-day ($27.52), 100-day ($23.27), and 200-day ($20.69) moving averages — a textbook bullish alignment. However, the stock has pulled back slightly from recent highs, trading below both the 5-day ($36.45) and 10-day ($37.70) moving averages, suggesting some near-term consolidation after the recent surge.
The overall technical setup is highly supportive heading into earnings, with the stock maintaining a strong uptrend structure across all timeframes. The slight pullback from very short-term moving averages may actually be healthy, potentially relieving some overbought pressure while keeping the broader uptrend intact. The key risk is that elevated technical momentum has set a high bar — any disappointment could trigger an outsized reversal given how extended the rally has become.
